StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.71−0.21 (-1.92%)

Close on Nov 17, 2026Market cap $654.78MP/E –Yield –

Janux Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Janux Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$41.25M. For fiscal 2025 it was -$82.24M. The highest annual figure on record is -$4.37M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$82.24M–
FY2024Dec 31, 2024-$43.81M–
FY2023Dec 31, 2023-$50.58M–
FY2022Dec 31, 2022-$42.92M–
FY2021Dec 31, 2021-$16.98M–
FY2020Dec 31, 2020-$4.37M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.48M–
Q1 FY2026Mar 31, 2026-$12.34M–
Q4 FY2025Dec 31, 2025-$28.54M–
Q3 FY2025Sep 30, 2025-$12.86M–
Q2 FY2025Jun 30, 2025-$23.81M–
Q1 FY2025Mar 31, 2025-$17.02M–
Q4 FY2024Dec 31, 2024-$16.73M–
Q3 FY2024Sep 30, 2024-$2.23M–
Q2 FY2024Jun 30, 2024-$10.02M–
Q1 FY2024Mar 31, 2024-$14.84M–
Q4 FY2023Dec 31, 2023-$9.90M–
Q3 FY2023Sep 30, 2023-$11.71M–
Q2 FY2023Jun 30, 2023-$15.05M–
Q1 FY2023Mar 31, 2023-$13.91M–
Q4 FY2022Dec 31, 2022-$11.91M–
Q3 FY2022Sep 30, 2022-$13.41M–
Q2 FY2022Jun 30, 2022-$6.07M–
Q1 FY2022Mar 31, 2022-$11.52M-307.1%
Q4 FY2021Dec 31, 2021-$10.48M–
Q3 FY2021Sep 30, 2021-$5.85M–
Q2 FY2021Jun 30, 2021-$6.20M–
Q1 FY2021Mar 31, 2021$5.56M–
Q4 FY2020Dec 31, 2020-$1.63M–
Q3 FY2020Sep 30, 2020-$1.08M–

More Janux Therapeutics figures

See a number that looks wrong?